ADIM
HALO icon

Alpha DNA Investment Management’s Halozyme HALO Stock Holding History

Alpha DNA Investment Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,109
Closed -$483K – 85
2024
Q4 		$483K Buy
10,109
+695
+7% +$35.6K 0.18% 113
2024
Q3 		$539K Buy
9,414
+938
+11% +$53.8K 0.2% 101
2024
Q2 		$444K Buy
8,476
+1,800
+27% +$78.9K 0.17% 136
2024
Q1 		$272K Buy
+6,676
New +$250K 0.1% 187
2021
Q2 		– Sell
-109
Closed -$4K – 329
2021
Q1 		$4K Buy
+109
New +$4.98K ﹤0.01% 409

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Alpha DNA Investment Management's HALO Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Halozyme (HALO) in Q1 2025, closing a stake of 10,109 shares — an estimated $483K sold.

Alpha DNA Investment Management first reported a position in HALO in Q1 2021 and held it in 5 quarters. The position peaked at $539K in Q3 2024. 550 funds tracked by Wall St. Rank hold HALO as of Q1 2025.

  • Alpha DNA Investment Management reported no remaining Halozyme position as of Q1 2025 after selling out during the quarter.
  • Alpha DNA Investment Management sold 10,109 Halozyme shares in Q1 2025, an estimated $483K.
  • Alpha DNA Investment Management first reported a position in Halozyme in Q1 2021 and held it in 5 quarters.
  • Alpha DNA Investment Management's Halozyme position peaked at $539K in Q3 2024.
  • 550 funds tracked by Wall St. Rank held Halozyme as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.